Progyny (PGNY) Earnings Date & Reports

Key Takeaways

• Progyny reported third quarter 2026 revenue of $341.3 million, up 8.9% year over year and essentially in line with consensus estimates of $340.9 million.
• Adjusted earnings per share (EPS) came in at $0.52, about 2% above the analyst consensus estimate of $0.51.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $58.4 million, reflecting a 17.1% margin and slightly beating expectations.
• Management guided fourth quarter 2026 revenue to a midpoint of roughly $354.7 million and lifted full-year adjusted EPS guidance to a midpoint near $2.11.
• The company added a record 1.3 million new covered lives and more than 85 new clients during its 2026 selling season, with near 100% client retention.
• Get more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Explore Trending AI Robots for additional market insights and automated trading ideas.

Earnings Context and Why It Matters

Progyny is a leading provider of fertility and family-building benefits, serving employers and health plans that sponsor coverage for their members. Its quarterly results matter because they reveal both the health of employer demand for fertility benefits and the company's ability to convert that demand into profitable growth. After absorbing the loss of a large former client that had been under a transition-of-care agreement through mid-2025, Progyny has spent 2026 rebuilding its revenue base. This report was closely watched for signs of renewed growth, margin stability, and the strength of its annual selling season, which determines client additions and covered lives for the following year.

Reported Results

Progyny delivered third quarter revenue of $341.3 million, an 8.9% increase over the prior-year period and above the midpoint of its own guidance, essentially matching the consensus estimate of $340.9 million. Excluding the contribution from a large former client, revenue grew roughly 11% over the first nine months of the year.

Adjusted EPS of $0.52 beat consensus by about 2%, while adjusted EBITDA of $58.4 million came in modestly ahead of the $57.9 million expected. Gross margin expanded 130 basis points year over year, driven by care management efficiencies and lower stock-based compensation expense.

On guidance, management set fourth quarter 2026 revenue at a midpoint of approximately $354.7 million, in line with analyst expectations, and pointed to a full-year adjusted EPS midpoint near $2.11. Operating cash flow exceeded $56 million in the quarter, extending a streak of seven consecutive quarters above $200 million on a trailing twelve-month basis.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors following earnings-driven moves may find it useful for spotting related opportunities across the healthcare and benefits-services sector.

Market Reaction and Investor Sentiment

The third quarter report reinforced the view that Progyny has moved past the revenue headwind created by a departed large client and re-established a clearer growth trajectory. Results that met or modestly beat expectations, combined with a record selling season, pointed to a stabilizing demand environment for employer-sponsored fertility benefits. Investor sentiment heading into the report had centered on whether the company could sustain mid-to-high single-digit growth while preserving margins, and the results offered largely affirmative signals. Key areas of focus included utilization trends, which management said reverted to the higher end of historical ranges, and retention, which remained near 100% for the 2027 plan year.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether the momentum from Progyny's record selling season translates into sustained revenue growth through 2027. The addition of 1.3 million new covered lives and more than 85 new clients provides a visible tailwind, but the timing of when those lives begin generating revenue will shape near-term results.

Margin dynamics remain another key consideration. Management has continued to invest in expanding its product platform while holding trailing twelve-month adjusted EBITDA margin near 17.1%. The ability to convert efficiency gains into both margin stability and competitive pricing will be an important signal of long-term profitability.

Finally, the competitive landscape and newer offerings such as Progyny Select, the company's fully insured market product, warrant monitoring. While Select was an immaterial contributor this season, management expects it to become a meaningful growth driver over time. Pharmacy program adoption among new clients, which management cited as near 100%, also offers a potential avenue for incremental revenue expansion.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations